Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring by 理쒖쁺�뱷 et al.
76
Copyright © 2014 Asian Pacific Prostate Society (APPS)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://p-international.org/
pISSN: 2287-8882 • eISSN: 2287-903X 
P R O S T A T E  
INTERNATIONAL
Analysis of different tumor volume thresholds of  
insignificant prostate cancer and their implications for 
active surveillance patient selection and monitoring
Dong Hoon Lee, Kyo Chul Koo1, Seung Hwan Lee1, Koon Ho Rha1, Young Deuk Choi1, Sung Joon Hong1,  
Byung Ha Chung1
Department of Urology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital,  
Pusan National University School of Medicine, Yangsan, Korea
1Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
Purpose: We compared oncological outcomes according to tumor volume (TV) thresholds defining both classical and updated 
insignificant prostate cancer (IPC), since the TV threshold can be used as clinical parameter for active surveillance.
Methods: Between 2001 and 2012, we retrospectively analyzed 331 organ-confined prostate cancer patients who had preoperative 
Gleason score 6, preoperative PSA under 10 ng/mL and pathologic TV less than 1.3 mL. Among them, 81 of 331 (24.5%) had Gleason 
grade 4/5 disease postoperatively. Patients were stratified into two groups: (1) TV less than 0.5 mL, using the classical definition; and (2) 
TV between 0.5 mL and 1.3 mL, using the range of updated definition. We compared biochemical recurrence (BCR)-free survival and 
identified independent predictors of BCR in each group.  
Results: Group 2 had more Gleason grade 4/5 disease than group 1 (P<0.001). On multivariate analysis, Gleason grade 4/5 disease 
was not associated with BCR in group 1 (P=0.132). However, it was an independent predictor for BCR in group 2 (P=0.042). BCR-free 
survival were not significantly different according to the presence of Gleason grade 4/5 disease in group 1 (P=0.115). However, in 
group 2, it was significantly different according to the presence of Gleason grade 4/5 disease (P=0.041).
Conclusions: Although the TV thresholds of the two definitions of IPC vary only slightly, this difference was enough to result in 
different clinical course if Gleason grade 4/5 disease was present. Therefore, the updated IPC TV threshold should be carefully applied 
as clinical parameter for active surveillance.
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INTRODUCTION
Urologists commonly use the classical definition of insignifi-
cant prostate cancer (IPC), which describes cases as organ-
confined, Gleason 6 disease with tumor volume (TV) < 0.5 
mL [1]. The TV threshold of this definition was suggested by 
Stamey et al. [2], who used a cystoprostatectomy study. This 
definition has also been used to select ideal active surveil-
lance (AS) candidates [3]. Recently, Wolters et al. [4] intro-
duced an updated TV threshold for IPC based on their own 
study cohort using a method similar to that of Stamey et al. 
[2]. This study concluded that the TV threshold of IPC may be 
increased up to 1.3 mL in cases of organ-confined prostate 
cancer without Gleason grade 4/5 disease. Using this updated 
definition of IPC, the rate of misclassification for AS selection 
according to TV could be decreased [5].
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thologist. Transverse whole-mount step section specimens 
were obtained at 3–4 mm intervals on a parallel plane, and 
the genitourinary pathologist reported results according to a 
standardized processing and reporting protocol. TV was de-
termined as part of the routine pathological assessment by vi-
sual estimation, as follows: The tumor area was outlined and 
x and y diameters were measured. The tumor area was then 
multiplied by its depth, based on the presence of the tumor 
in subsequent sections and the thickness of the sections. The 
total sum of all foci of tumor was the estimated TV. After sur-
gery, a serum PSA assay was performed in the first 2 months 
and then every 3–4 months before biochemical recurrence 
(BCR). BCR was defined as a sustained increase in total se-
rum PSA levels to ≥ 0.2 ng/mL after RP.
 We divided the study cohort into two groups according to 
the two TV thresholds used for the definition of IPC: (1) The 
TV threshold of the classical definition, 0.5 mL; and (2) The 
TV threshold for the updated definition, 1.3 mL. To compare 
clinicopathologic outcomes, chi-square tests and indepen-
dent t-tests were used for categorical and continuous vari-
ables, respectively. We compared BCR-free survival rates, and 
calculated the actual risk of BCR, between the two groups us-
ing the Kaplan-Meier method. We also independently identi-
fied risk factors for BCR using the Cox proportional hazards 
model in each group. All statistical analyses were performed 
using PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). A P-
value ≤ 0.05 was considered statistically significant.
RESULTS
Baseline patient characteristics are shown in Table 1. The 
mean patient age was 62.6 years, and the mean preoperative 
PSA level was 5.53 ng/mL. The mean TV was 0.49 ± 0.40 mL. 
The number of patients with TV less than 0.5 mL or between 
0.5 mL and 1.3 mL was 195 (58.9%) and 136 (41.1%), respec-
tively. A total of 250 (75.5%), 76 (23.0%), and 5 patients (1.5%) 
had a postoperative GS ≤ 6, 7, and 8–10, respectively. At the 
time of analysis, 24 patients (7.3%) had experienced BCR dur-
ing the mean follow-up period of 38 months. Comparing the 
two TV groups, preoperative PSA levels were not significantly 
different (P= 0.073). The group with TV less than 0.5 mL had 
significantly larger prostate volumes compared with the other 
group (P= 0.005). Postoperative GS was also significantly dif-
ferent according to TV (P< 0.001). The proportion of patients 
with postoperative GS ≤ 6, 7, and 8–10 was 85.1%, 13.8%, and 
1.0% in the group with TV less than 0.5 mL, while these pro-
portions were 61.8%, 36.0%, and 2.2% in the group with TV 
between 0.5 mL and 1.3 mL. Patients with TV less than 0.5 mL 
 However, whether the updated TV threshold can be used 
as a clinical parameter for selection of AS candidates remains 
unclear. According to recent reports, clinical TV analysis for 
selection of AS candidate using multiparameteric magnetic 
resonance imaging (MP-MRI) has become important and re-
liable as MP-MRI techniques have advanced [6-9]. Thus, de-
termining whether the TV threshold of the classical definition 
or that of the updated definition of IPC for AS is more safe is a 
key goal, considering the window of curability. The possibility 
of misclassification by Gleason upgrading in radical prosta-
tectomy (RP) specimens always exists among AS candidates 
[5,10,11]. We reasoned that the clinical TV parameters of the 
two IPC definitions should be evaluated in the context of AS, 
even if pathologists reported the presence of Gleason grade 
4/5 disease in RP specimens after urologists decided the in-
tervention during AS.
 The aim of the present study was to identify which TV 
threshold, the classical or the updated, is the most desirable 
clinical TV parameter for AS selection and monitoring. To 
this end, we compared oncologic outcomes using RP speci-
mens according to TV and the presence of Gleason grade 4/5 
disease in organ-confined prostate cancer patients having the 
following characteristics: (1) preoperative Gleason score (GS) 
6,(2) preoperative prostate-specific antigen (PSA) levels lower 
than 10 ng/mL, and (3) pathologic TVs less than 1.3 mL.
MATERIALS AND METHODS
We retrospectively analyzed 2,399 prostate cancer patients 
who underwent RP between 2001 and 2012. Of these patients, 
we selected those with preoperative GS 6 and preoperative 
PSA level under 10 ng/mL. Among this population, we identi-
fied 779 pathologically organ-confined prostate cancer pa-
tients who had no residual tumor. We also included patients 
with TV lower than 1.3 mL, leaving 362 patients in the final 
analysis. Among them, 31 patients with incomplete data were 
excluded. Therefore, the final study cohort consisted of 331 
patients. Of these patients, 81 (24.5%) had Gleason grade 4/5 
disease according to RP pathology. We hypothesized that 
these 81 patients would be misclassified AS candidates who 
had the possibility of Gleason upgrading in their RP speci-
mens, even though they had preoperative GS 6 and preopera-
tive PSA level under 10 ng/mL.
 We corrected clinical and pathological variables includ-
ing age, preoperative PSA level, prostate volume, pathologic 
stage, postoperative GS and TV. Postoperative GS and TV 
were determined from pathological evaluation. All RP speci-
mens were analyzed by an experienced genitourinary pa-
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were more likely to have a postoperative GS ≤ 6 than those 
who had TV between 0.5 mL and 1.3 mL. 
 Table 2 shows the Cox proportional hazards model for pre-
dicting BCR in each group. Multivariate analysis of patients 
with TV less than 0.5 mL revealed that age, preoperative PSA 
level, prostate volume, pathologic stage and the presence of 
high Gleason grade disease were not associated with BCR. 
However, in the patients with TV between 0.5 mL and 1.3 mL, 
the presence of Gleason grade 4/5 disease was determined 
to significantly increase the risk of BCR compared with other 
risk factors; the hazard ratio was 3.85 folds (P= 0.042).
  Kaplan-Meier analysis is shown in Fig. 1. In patients with 
TV less than 0.5 mL, BCR-free survival was not significantly 
different regardless of the presence of Gleason grade 4/5 
disease (P= 0.115) (Fig. 1A). However, in patients with TV 
between 0.5 mL and 1.3 mL, BCR-free survival varied sig-
nificantly according to the presence of Gleason grade 4/5 
disease (P= 0.041) (Fig. 1B). Prostate cancer patients with TV 
Table 1. Clinical and pathological characteristics
Characteristic TV≤0.5 mL
0.5 mL<
TV≤1.3 mL
P-value
No. of patients 195 136
Age (yr) 62.6±7.0 62.7±97.3 0.882
Preoperative PSA level (ng/mL) 5.40±1.83 5.77±1.79 0.073
Prostate volume (mL) 39.9±17.1 34.8±14.9 0.005
Pathologic stage 0.001
  pT2a/b 203 (74.1) 104 (43.7)
  pT2c 71 (25.9) 134 (56.3)
Postoperative Gleason score <0.001 
  ≤6 166 (85.1) 84 (61.8)
  7 27 (13.8) 49 (36.0)
  8-10 2 (1.0) 3 (2.2)
Presence of Gleason grade 4/5 29 (24.5) 52 (38.2) <0.001
Tumor volume (mL) 0.20±0.16 0.91±0.22 <0.001
Total follow-up period (mo) 37.6±24.5 38.6±26.3 0.745
Biochemical recurrence 13 (6.7) 11 (8.1) 0.670
Values are presented as mean±standard deviation or number (%).
TV, tumor volume; PSA, prostate-specific antigen.
Table 2. Multivariate analysis of factors predictive of biochemical recurrence according to tumor volume
Variable
TV≤0.5 mL 0.5 mL<TV≤1.3 mL
HR 95% CI P-value HR 95% CI P-value
Age 0.98 0.90–1.08 0.725 0.97 0.89–1.06 0.479
Preoperative PSA level (ng/mL) 0.93 0.66–1.29 0.652 0.99 0.69–1.45 0.994
Prostate volume (mL) 1.01 0.98–1.05 0.374 0.99 0.96–1.04 0.883
Pathologic stage
  pT2a/b Ref. - - Ref. - -
  pT2c 1.28 0.36–4.53 0.698 0.58 0.17–1.95 0.377
Presence of Gleason grade 4/5 2.53 0.76–8.44 0.132 3.85 1.05–14.15 0.042
TV, tumor volume; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.
Fig. 1. Kaplan-Meier curve for biochemical recurrence-free survival according to tumor volume and the presence of high Gleason 
grade disease after radical prostatectomy. (A) Tumor volume less than 0.5 mL. (B) Tumor volume between 0.5 mL and 1.3 mL.
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between 0.5 mL and 1.3 mL showed an increased risk of BCR 
if they had Gleason grade 4/5 disease, even if the patient was 
an organ-confined prostate cancer patient with a preopera-
tive PSA level lower than 10 ng/mL.
DISCUSSION
AS has become a reasonable treatment option for low-risk 
prostate cancer patients; furthermore, the number of low-risk 
prostate cancer patients has increased. Klotz et al. [12] dem-
onstrated that AS can be a treatment option for low-risk pros-
tate cancer patients in a prospective study. Prostate cancer pa-
tients with IPC could also be ideal AS candidates, considering 
the indolent nature of IPC. Thus, urologists have attempted to 
select appropriate IPC patients for AS using the classical defi-
nition of IPC as organ-confined, Gleason 6 disease with TV 
<0.5 mL [13]. TV is one of the most important criteria in the 
definition of IPC.
 To select ideal AS candidates with IPC, several AS protocols 
have used clinical stage, preoperative PSA level, and the pros-
tate biopsy profile as inclusion criteria [14-18]. However, it is 
difficult to precisely select ideal AS candidates using the cur-
rent inclusion criteria because the possibility of misclassifica-
tion always exists for RP specimens. Moreover, Gleason up-
grading and pathologic upstaging can occur frequently, even 
when stringent AS selection criteria are used. Furthermore, 
misclassification by TV also occurs frequently, since predict-
ing pathologic TV is difficult using the current AS inclusion 
criteria, which only include prostate biopsy profiles, and this 
misclassification could affect AS monitoring. Also, the detec-
tion of prostate cancer progression during AS monitoring is 
as important as AS selection. However, the best parameter 
for the identification of prostate cancer progression is still 
unclear. Several authors have suggested follow-up criteria 
including digital rectal examination, PSA follow-up and re-
peated prostate biopsy that should be used to decide whether 
intervention should be performed during AS [19-22]. Regard-
ing imaging parameters, most of the literature does not rec-
ommend transrectal ultrasound (TRUS), since their efficacy 
has not been proven as a measure of progression during AS 
[23,24]. However, we reasoned that MP-MRI could play a role 
in selecting AS candidates and in monitoring the progression 
of prostate cancer.
 In our previous study [6], we found that the prediction of AS 
candidates could be improved by MP-MRI. Moreover, recent 
studies have also concluded that MP-MRI can help predict TV 
and bilateral tumor rates in unilateral low-risk prostate cancer 
patients; furthermore, MP-MRI is useful in assessing the clini-
cal significance of prostate cancer in men at risk prior to biop-
sy [7,8]. Furthermore, Turkbey et al. [9] reported that MP-MRI 
was better for estimating index TV and was more accurate in 
predicting prostate TV larger than 0.5 cm3 than other clinical 
variables. We hypothesized that these advantages of MP-MRI 
could apply to AS follow-up, as a useful image parameter. In 
other words, if urologists could calculate clinical TV using 
MP-MRI, this measurement would be a useful parameter in 
deciding whether a patient should be selected for AS, and 
also for deciding whether intervention is required during AS. 
However, it is still unclear which clinical TV threshold is the 
best parameter to be used for AS selection and monitoring; 
therefore, many investigators simply use the TV threshold in 
the classical definition of IPC for AS-correlated studies.
 Meanwhile, Wolters et al. [4] introduced the idea that the 
TV threshold of IPC could be increased to at least 1.3 mL. Us-
ing this definition as the clinical TV parameter, the number of 
AS candidates would be increased. Urologists could use the 
updated definition for the prostate cancer patients who met 
AS protocols to analysis clinical TV using MP-MRI. However, 
an important issue should also be discussed. The safety of the 
updated definition of IPC did not validate for AS candidate 
considering the possibility of Gleason upgrading. Even if an 
AS candidate who met the stringent AS protocol had a suspi-
cious tumor lesion according to MP-MRI analysis, urologists 
would be unable to guarantee that the suspicious tumor le-
sion detected by MP-MRI was GS 6 disease. The possibility of 
the presence of Gleason grade 4/5 disease always exists due 
to sampling bias, variations in needle biopsy and pathologist-
dependent variation in Gleason grading. Even though the 
difference between TV measurements used for defining clas-
sical and updated IPC appears small, this difference could 
lead to large differences in oncological outcomes, depending 
on the presence of Gleason grade 4/5 disease.
 In the present study, the presence of Gleason grade 4/5 
disease was not associated with BCR among prostate cancer 
patients with TV less than 0.5 mL. This TV threshold defines 
classical IPC. However, among patients with TV between 
0.5 and 1.3 mL, a range below the threshold of the updated 
definition of IPC, the presence of Gleason grade 4/5 disease 
was an independent predictor of BCR. These patients showed 
different clinical courses according to their postoperative GS 
even though they were all organ-confined prostate cancer pa-
tients with preoperative PSA levels under 10 ng/mL. We rea-
soned that this observation could be relevant to AS selection 
and monitoring. If AS candidates exhibit clinical TV between 
0.5 and 1.3 mL according to MP-MRI, even under the range 
of TV threshold of updated IPC, urologists should carefully 
Lee, et al. Tumor volume for active surveillance
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re-evaluate and reconfirm their suitability as AS candidates, 
since they could miss their windows of curability if they ex-
hibit unexpected Gleason grade 4/5 disease. Also, if patients 
receiving AS show progression to clinical TV larger than 0.5 
mL, urologists must consider either intervention or stringent 
reclassification using a repeat biopsy to rule out the presence 
of Gleason grade 4/5 disease.
 Our study has several limitations. For instance, it is a small 
retrospective study using RP specimens, and we have no data 
regarding the oncological outcomes of AS patients according 
to the two clinical TV thresholds. Rather, we compared onco-
logic outcomes according to the pathologic definition of TV 
used in the classical definition and the updated definition of 
IPC. However, we found that the small difference between the 
two TVs used in the different definitions of IPC could be as-
sociated with quite different clinical courses if Gleason grade 
4/5 disease existed in the AS candidate. We validated the 
oncologic safety of TV threshold of updated definition of IPC, 
even though this definition was not usually used in clinical 
practice [25], because urologists may apply the updated defi-
nition for AS more often to low-risk prostate cancer patients 
considering only the beneficiaries of AS. Because of this, we 
thought that AS candidates who had clinical TV larger than 
0.5 mL are carefully reconfirmed or reclassified not to miss 
the window of curability. 
 Another limitation is the reliability of clinical TV analysis 
for determining the application of AS in clinical practice. In 
fact, the present study assumes that MP-MRI contributes 
to the decision-making process regarding AS selection and 
monitoring. This issue is still debated by urologists; Several 
studies have suggested that MP-MRI may be a more precise 
imaging tool for localizing prostate cancer and predicting TV 
in low-risk prostate cancer patients including AS candidates 
[26-28]. However, another study demonstrated that clinical 
TV measurement using MP-MRI could under-estimate in 
comparison with pathologic TV after RP [29]. Nevertheless, as 
MP-MRI techniques advance, we believe that this tool will be-
come more useful in both selecting and monitoring AS candi-
dates. Therefore, it is important to establish accurate criteria, 
including a clinical TV threshold, for the use of MP-MRI data 
in selecting candidates for AS. From this point of view, the 
present study may contribute to future efforts in AS selection 
and monitoring.
  In conclusion, although the difference between the TV 
thresholds in the two definitions of IPC is relatively small, this 
difference could account for varying clinical course if Gleason 
grade 4/5 disease exists in organ-confined prostate cancer 
patients with a preoperative PSA level lower than 10 ng/mL. 
Therefore, considering the possibility of Gleason upgrading 
in AS candidates, the TV threshold in the updated definition 
of IPC should be carefully applied as a clinical TV threshold 
used for AS selection and monitoring. To further validate the 
use of this clinical TV parameter for AS selection and moni-
toring, larger patient studies and further long-term prospec-
tive studies will be required.
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